Pharmacological aspects of the safety of gliflozins

Pharmacological Research

Volumn 118, Issue , 2017, Pages 71-81

  Faillie, Jean Luc ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Adverse reactions; Drug safety; SGLT2 inhibitors; Sodium glucose transporters; Type 2 diabetes

Indexed keywords

CALCITRIOL; CANAGLIFLOZIN; CREATININE; DAPAGLIFLOZIN; EMPAGLIFLOZIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; PARATHYROID HORMONE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; LIPID;

ADRENAL TUMOR; BALANITIS; BLADDER CANCER; BREAST CANCER; BREAST FEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DEHYDRATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; FRACTURE; FUNGAL GENITAL INFECTION; GENITAL CANDIDIASIS; GENITAL TRACT INFECTION; GLUCOSE ABSORPTION; GLUCOSE TRANSPORT; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPERGLUCAGONEMIA; HYPERKALEMIA; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; HYPOTENSION; HYPOVOLEMIA; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; KIDNEY CANCER; LIVER TOXICITY; LUNG CANCER; MALABSORPTION; MALIGNANT NEOPLASM; MAXIMUM PLASMA CONCENTRATION; MELANOMA; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; OSMOTIC DIURESIS; PHARMACODYNAMICS; PHEOCHROMOCYTOMA; PLASMA PROTEIN BINDING; PREGNANCY; REVIEW; SIDE EFFECT; TOXIC HEPATITIS; URINARY TRACT INFECTION; VAGINITIS; VOLUME OF DISTRIBUTION; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; GLOMERULUS FILTRATION RATE;

ANIMALS; BENZHYDRYL COMPOUNDS; FRACTURES, BONE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; KETOSIS; LIPIDS; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85002525061     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.07.001     Document Type: Review

References (79)

1. [1] Wright, E.M., Glucose transport families SLC5 and SLC50. Mol. Aspects Med. 34 (2013), 183–196.
2. [2] Wright, E.M., Loo, D.D., Hirayama, B.A., Biology of human sodium glucose transporters. Physiol. Rev. 91 (2011), 733–794.
3. [3] Hummel, C.S., Lu, C., Loo, D.D., Hirayama, B.A., Voss, A.A., Wright, E.M., Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am. J. Physiol. Cell Physiol. 300 (2011), C14–21.
4. [4] Vallon, V., Platt, K.A., Cunard, R., et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J. Am. Soc. Nephrol. 22 (2011), 104–112.
5. [5] Santer, R., Kinner, M., Lassen, C.L., et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J. Am. Soc. Nephrol. 14 (2003), 2873–2882.
6. [6] Chao, E.C., Henry, R.R., SGLT2 inhibition–a novel strategy for diabetes treatment. Nat. Rev. Drug Discov. 9 (2010), 551–559.
7. [7] Mackenzie, B., Loo, D.D., Panayotova-Heiermann M, Wright EM. Biophysical characteristics of the pig kidney Na+/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2. J. Biol. Chem. 271 (1996), 32678–32683.
8. [8] Mackenzie, B., Loo, D.D., Wright, E.M., Relationships between Na+/glucose cotransporter (SGLT1) currents and fluxes. J. Membr. Biol. 162 (1998), 101–106.
9. [9] Rahmoune, H., Thompson, P.W., Ward, J.M., Smith, C.D., Hong, G., Brown, J., Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54 (2005), 3427–3434.
10. [10] Kothinti, R.K., Blodgett, A.B., North, P.E., Roman, R.J., Tabatabai, N.M., A novel SGLT is expressed in the human kidney. Eur. J. Pharmacol. 690 (2012), 77–83.
11. [11] Pruijm, M., Wuerzner, G., Maillard, M., et al. Glomerular hyperfiltration and increased proximal sodium reabsorption in subjects with type 2 diabetes or impaired fasting glucose in a population of the African region. Nephrol. Dial. Transplant. 25 (2010), 2225–2231.
12. [12] de Koninck, L., Observations sur les proprietes febrifuges de la phloridzine. Bull. Soc. Med. Gand 1 (1836), 75–110.
13. [13] Ehrenkranz, J.R., Lewis, N.G., Kahn, C.R., Roth, J., Phlorizin a review. Diabetes Metab. Res. Rev. 21 (2005), 31–38.
14. [14] Amsler, K., Cook, J., Development of a Na-dependent hexose transport in a cultured line of porcine kidney cells. Am. J. Physiol. 242 (1982), C94–C101.
15. [15] Rossetti, L., Smith, D., Shulman, G.I., Papachristou, D., DeFronzo, R.A., Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J. Clin. Invest. 79 (1987), 1510–1515.
16. [16] Malhotra, A., Kudyar, S., Gupta, A.K., Kudyar, R.P., Malhotra, P., Sodium glucose co-transporter inhibitors – a new class of old drugs. Int. J. Appl. Basic Med. Res. 5 (2015), 161–163.
17. [17] Isaji, M., SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int. 2011:Suppl (2016), S14–9.
18. [18] Heise, T., Seewaldt-Becker, E., Macha, S., et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes. Metab. 15 (2013), 613–621.
19. [19] Scheen, A.J., Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin. Drug Metab. Toxicol. 10 (2014), 647–663.
20. [20] Vick, H., Diedrich, D.F., Baumann, K., Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs. Am. J. Physiol. 224 (1973), 552–557.
21. [21] Abdul-Ghani, M.A., DeFronzo, R.A., Norton, L., Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 62 (2013), 3324–3328.
22. [22] Liu, J.J., Lee, T., DeFronzo, R.A., Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans. Diabetes 61 (2012), 2199–2204.
23. [23] Vasilakou, D., Karagiannis, T., Athanasiadou, E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann. Intern. Med. 159 (2013), 262–274.
24. [24] Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373 (2015), 2117–2128.
25. [25] UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865.
26. [26] Dormandy, J.A., Charbonnel, B., Eckland, D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
27. [27] Muskiet, M.H., van Raalte, D.H., van Bommel, E.J., Smits, M.M., Tonneijck, L., Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol. 3 (2015), 928–929.
28. [28] Ceriello, A., Genovese, S., Mannucci, E., Gronda, E., Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol. 3 (2015), 929–930.
29. [29] Grempler, R., Thomas, L., Eckhardt, M., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab. 14 (2012), 83–90.
30. [30] Kurosaki, E., Ogasawara, H., Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol. Ther. 139 (2013), 51–59.
31. [31] Devineni, D., Curtin, C.R., Polidori, D., et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J. Clin. Pharmacol. 53 (2013), 601–610.
32. [32] Scheen, A.J., Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin. Pharmacokinet. 53 (2014), 213–225.
33. [33] Kasichayanula, S., Chang, M., Hasegawa, M., et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes. Metab. 13 (2011), 357–365.
34. [34] European Medicines Agency Invokana (canagliflozin), EPAR Public Assessment Report. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002649/WC500156457.pdf.
35. [35] Palazzo, M., Gariboldi, S., Zanobbio, L., et al. Sodium-dependent glucose transporter-1 as a novel immunological player in the intestinal mucosa. J. Immunol. 181 (2008), 3126–3136.
36. [36] Johnsson, K.M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S.J., List, J.F., Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J. Diabetes Complications 27 (2013), 479–484.
37. [37] US Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm.
38. [38] US Food and Drug Administration. FDA briefing document: NDA 202293 dapagliflozin 5 and 10 mg. July 19, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/Committees-MeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262994.pdf.
39. [39] US Food and Drug Administration. FDA background document, BMS-512148 NDA 202293 dapagliflozin. 2013. http://www.fda.gov/downloads/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm378079.pdf.
40. [40] Pelucchi, C., Bosetti, C., Negri, E., Malvezzi, M., La Vecchia, C., Mechanisms of disease: the epidemiology of bladder cancer. Nat. Clin. Pract. Urol. 3 (2006), 327–340.
41. [41] Lin, H.W., Tseng, C.H., A review on the relationship between SGLT2 inhibitors and cancer. Int. J. Endocrinol., 2014, 2014, 719578.
42. [42] Reilly, T.P., Graziano, M.J., Janovitz, E.B., et al. Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther. 5 (2014), 73–96.
43. [43] Abdul-Ghani, M.A., DeFronzo, R.A., Dapagliflozin for the treatment of type 2 diabetes. Expert Opin. Pharmacother. 14 (2013), 1695–1703.
44. [44] US Food and Drug Administration. Advisory Committee Nonclinical Briefing Document. FDA briefing document: NDA 202293 dapagliflozin 5 and 10 mg. July 19, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/Committees-MeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262994.pdf.
45. [45] US Food and Drug Administration. FDA Briefing Document, NDA 204042 Canagliflozin tablets. Advisory Committee Meeting: 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf.
46. [46] European Medicines Agency Summary of the risk management plan (RMP) for Jardiance (empagliflozin). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Risk-management-plan_summary/human/002677/WC500163291.pdf.
47. [47] US Food and Drug Administration. Jardiance (empagliflozin). Medical Review. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204629Orig1s000MedR.pdf.
48. [48] Ishikawa, N., Oguri, T., Isobe, T., Fujitaka, K., Kohno, N., SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn. J. Cancer Res. 92 (2001), 874–879.
49. [49] European Medicines Agency Forxiga (dapagliflozin), EPAR Public Assessment Report., 2012 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002322/WC500136024.pdf.
50. [50] Nauck, M.A., Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des. Dev. Ther. 8 (2014), 1335–1380.
51. [51] Jurczak, M.J., Lee, H.Y., Birkenfeld, A.L., et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60 (2011), 890–898.
52. [52] European Medicines Agency SGLT2 inhibitors. Opinion provided by Committee for Medicinal Products for Human Use. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors__20/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use/WC500203178.pdf.
53. [53] Peters, A.L., Buschur, E.O., Buse, J.B., Cohan, P., Diner, J.C., Hirsch, I.B., Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1687–1693.
54. [54] Munro, J.F., Campbell, I.W., McCuish, A.C., Duncan, L.J., Euglycaemic diabetic ketoacidosis. Br. Med. J. 2 (1973), 578–580.
55. [55] Thawabi, M., Studyvin, S., Euglycemic diabetic ketoacidosis, a misleading presentation of diabetic ketoacidosis. N. Am. J. Med. Sci. 7 (2015), 291–294.
56. [56] Ferrannini, E., Muscelli, E., Frascerra, S., et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 124 (2014), 499–508.
57. [57] Merovci, A., Solis-Herrera, C., Daniele, G., et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 124 (2014), 509–514.
58. [58] Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G.M., Unger, R.H., Insulin within islets is a physiologic glucagon release inhibitor. J. Clin. Invest. 74 (1984), 2296–2299.
59. [59] Bonner, C., Kerr-Conte, J., Gmyr, V., et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat. Med. 21 (2015), 512–517.
60. [60] Oemar, B.S., Byrd, D.J., Brodehl, J., Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0). Clin. Nephrol. 27 (1987), 156–160.
61. [61] Taylor, S.I., Blau, J.E., Rother, K.I., SGLT2 inhibitors may predispose to ketoacidosis. J. Clin. Endocrinol. Metab. 100 (2015), 2849–2852.
62. [62] Cohen, J.J., Berglund, F., Lotspeich, W.D., Renal tubular reabsorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin. Am. J. Physiol. 184 (1956), 91–96.
63. [63] Rosenstock, J., Ferrannini, E., Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38 (2015), 1638–1642.
64. [64] Kohan, D.E., Fioretto, P., Tang, W., List, J.F., Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 85 (2014), 962–971.
65. [65] Watts, N.B., Bilezikian, J.P., Usiskin, K., et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 101 (2016), 157–166.
66. [66] Taylor, S.I., Blau, J.E., Rother, K.I., Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 3 (2015), 8–10.
67. [67] Bode, B., Stenlof, K., Harris, S., et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes. Metab. 17 (2015), 294–303.
68. [68] Bilezikian, J.P., Watts, N.B., Usiskin, K., et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J. Clin. Endocrinol. Metab. 101 (2016), 44–51.
69. [69] Vallon, V., Richter, K., Blantz, R.C., Thomson, S., Osswald, H., Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J. Am. Soc. Nephrol. 10 (1999), 2569–2576.
70. [70] Weidmann, P., Ferrari, P., Central role of sodium in hypertension in diabetic subjects. Diabetes Care 14 (1991), 220–232.
71. [71] Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
72. [72] Bertinat, R., Nualart, F., Yanez, A.J., SGLT2 inhibitors: glucotoxicity and tumorigenesis downstream the renal proximal tubule. J. Cell. Physiol. 231 (2016), 1635–1637.
73. [73] Weir, M.R., Moser, M., Diuretics and beta-blockers: is there a risk for dyslipidemia. Am. Heart J. 139 (2000), 174–183.
74. [74] Devenny, J.J., Godonis, H.E., Harvey, S.J., Rooney, S., Cullen, M.J., Pelleymounter, M.A., Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 20 (2012), 1645–1652.
75. [75] Banerjee, S.K., McGaffin, K.R., Pastor-Soler, N.M., Ahmad, F., SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc. Res. 84 (2009), 111–118.
76. [76] Chen, J., Williams, S., Ho, S., et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 1 (2010), 57–92.
77. [77] Zhou, L., Cryan, E.V., D'Andrea, M.R., Belkowski, S., Conway, B.R., Demarest, K.T., Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J. Cell. Biochem. 90 (2003), 339–346.
78. [78] Wu, J.H., Foote, C., Blomster, J., et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 4 (2016), 411–419.
79. [79] EMA reviews diabetes medicine canagliflozin. Review follows data on toe amputations in ongoing study. 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2_inhibitors_(previously_Canagliflozin)/human_referral_prac_000059.jsp&mid=WC0b01ac05805c516f.